170 related articles for article (PubMed ID: 8194194)
1. 1 alpha,25-Dihydroxyvitamin D3 inhibits the invasive potential of human breast cancer cells in vitro.
Hansen CM; Frandsen TL; Brünner N; Binderup L
Clin Exp Metastasis; 1994 May; 12(3):195-202. PubMed ID: 8194194
[TBL] [Abstract][Full Text] [Related]
2. Regulation of epidermal growth factor receptor levels by 1,25-dihydroxyvitamin D3 in human breast cancer cells.
Koga M; Eisman JA; Sutherland RL
Cancer Res; 1988 May; 48(10):2734-9. PubMed ID: 2834048
[TBL] [Abstract][Full Text] [Related]
3. 1alpha,25-dihydroxyvitamin D3 inhibits in vitro invasiveness through the extracellular matrix and in vivo pulmonary metastasis of B16 mouse melanoma.
Yudoh K; Matsuno H; Kimura T
J Lab Clin Med; 1999 Feb; 133(2):120-8. PubMed ID: 9989763
[TBL] [Abstract][Full Text] [Related]
4. Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity.
Ly LH; Zhao XY; Holloway L; Feldman D
Endocrinology; 1999 May; 140(5):2071-6. PubMed ID: 10218956
[TBL] [Abstract][Full Text] [Related]
5. Effects of 1,25-dihydroxyvitamin D3 on tumor cell invasion to the extracellular matrix in human fibrosarcoma HT1080 cells and its correlation with laminin.
Yudoh K; Matsui H; Tsuji H
Tumour Biol; 1997; 18(2):69-79. PubMed ID: 9222304
[TBL] [Abstract][Full Text] [Related]
6. The anti-proliferative effects of 1alpha,25(OH)2D3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression.
Campbell MJ; Gombart AF; Kwok SH; Park S; Koeffler HP
Oncogene; 2000 Oct; 19(44):5091-7. PubMed ID: 11042697
[TBL] [Abstract][Full Text] [Related]
7. 1alpha,25-Dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells.
Swami S; Krishnan AV; Feldman D
Clin Cancer Res; 2000 Aug; 6(8):3371-9. PubMed ID: 10955825
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of insulin- and insulin-like growth factor-I-stimulated growth of human breast cancer cells by 1,25-dihydroxyvitamin D3 and the vitamin D3 analogue EB1089.
Vink-van Wijngaarden T; Pols HA; Buurman CJ; Birkenhäger JC; van Leeuwen JP
Eur J Cancer; 1996 May; 32A(5):842-8. PubMed ID: 9081364
[TBL] [Abstract][Full Text] [Related]
9. 1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms.
Zhao XY; Peehl DM; Navone NM; Feldman D
Endocrinology; 2000 Jul; 141(7):2548-56. PubMed ID: 10875257
[TBL] [Abstract][Full Text] [Related]
10. Vitamin D and systemic cancer: is this relevant to malignant melanoma?
Osborne JE; Hutchinson PE
Br J Dermatol; 2002 Aug; 147(2):197-213. PubMed ID: 12174089
[TBL] [Abstract][Full Text] [Related]
11. Effect of 1,25-dihydroxyvitamin D3 on mouse mammary tumor (GR) cells: evidence for receptors, cellular uptake, inhibition of growth and alteration in morphology at physiologic concentrations of hormone.
Gross M; Kost SB; Ennis B; Stumpf W; Kumar R
J Bone Miner Res; 1986 Oct; 1(5):457-67. PubMed ID: 2845731
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptor and vitamin D receptor in human ovarian cancer: growth stimulation and inhibition by ligands.
Ahonen MH; Zhuang YH; Aine R; Ylikomi T; Tuohimaa P
Int J Cancer; 2000 Apr; 86(1):40-6. PubMed ID: 10728592
[TBL] [Abstract][Full Text] [Related]
13. Stable expression of the nuclear vitamin D receptor in the human prostatic carcinoma cell line JCA-1: evidence that the antiproliferative effects of 1 alpha, 25-dihydroxyvitamin D3 are mediated exclusively through the genomic signaling pathway.
Hedlund TE; Moffatt KA; Miller GJ
Endocrinology; 1996 May; 137(5):1554-61. PubMed ID: 8612485
[TBL] [Abstract][Full Text] [Related]
14. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.
Skowronski RJ; Peehl DM; Feldman D
Endocrinology; 1995 Jan; 136(1):20-6. PubMed ID: 7530193
[TBL] [Abstract][Full Text] [Related]
15. Effects of 1,25-dihydroxyvitamin D3 on cell-cycle kinetics of T 47D human breast cancer cells.
Eisman JA; Sutherland RL; McMenemy ML; Fragonas JC; Musgrove EA; Pang GY
J Cell Physiol; 1989 Mar; 138(3):611-6. PubMed ID: 2925799
[TBL] [Abstract][Full Text] [Related]
16. Antiestrogen potentiation of antiproliferative effects of vitamin D3 analogues in breast cancer cells.
Love-Schimenti CD; Gibson DF; Ratnam AV; Bikle DD
Cancer Res; 1996 Jun; 56(12):2789-94. PubMed ID: 8665515
[TBL] [Abstract][Full Text] [Related]
17. 1 alpha, 25-Dihydroxyvitamin D3 specifically induces its own metabolism in a human cancer cell line.
Eisman JA; Sher E; Suva LJ; Frampton RJ; McLean FL
Endocrinology; 1984 Apr; 114(4):1225-31. PubMed ID: 6323135
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of 1,25-dihydroxyvitamin D3 and tetradecanoylphorbol acetate on cell cycle and apoptosis of MCF-7 cells and a vitamin D3-resistant variant.
Narvaez CJ; Welsh J
Endocrinology; 1997 Nov; 138(11):4690-8. PubMed ID: 9348195
[TBL] [Abstract][Full Text] [Related]
19. Vitamin D receptor in SH-SY5Y human neuroblastoma cells and effect of 1,25-dihydroxyvitamin D3 on cellular proliferation.
Celli A; Treves C; Stio M
Neurochem Int; 1999 Feb; 34(2):117-24. PubMed ID: 10213069
[TBL] [Abstract][Full Text] [Related]
20. Down-regulation of laminin-binding integrins by 1 alpha,25-dihydroxyvitamin D3 in human melanoma cells in vitro.
Hansen CM; Madsen MW; Arensbak B; Skak-Nielsen T; Latini S; Binderup L
Cell Adhes Commun; 1998 Mar; 5(2):109-20. PubMed ID: 9638332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]